News & Events about Repligen Corp.
Repligen (NASDAQ:RGEN Get Rating) had its price objective lowered by investment analysts at SVB Leerink from $230.00 to $200.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has an outperform rating on the biotechnology companys stock. SVB ...
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 41stAnnual J.P. Morgan Healthcare conference being held January 9-12 in San Francisco. Tony J. ...
Royal Bank of Canada started coverage on shares of Repligen (NASDAQ:RGEN Get Rating) in a research report report published on Tuesday, The Fly reports. The firm issued a sector perform rating and a $190.00 price target on the biotechnology companys stock. RGEN has been the topic of ...
Repligen Co. (NASDAQ:RGEN Get Rating) CEO Anthony Hunt sold 25,000 shares of the businesss stock in a transaction dated Friday, November 11th. The stock was sold at an average price of $200.00, for a total transaction of $5,000,000.00. Following the sale, the chief executive officer now directly ...
Thinking about trading options or stock in Laredo Petroleum, Repligen, Tesla, Amazon, or Advanced Micro Devices? Thinking about trading options or stock in Laredo Petroleum, Repligen, Tesla, Amazon, or Advanced Micro Devices? PR Newswire NEW YORK, Oct. 4, 2022 NEW YORK, Oct. 4, 2022 /PRNewswire...